No Data
No Data
心通醫療-B:2023年度報告
XinTong Medical-B (02160): Vitaflow Liberty receives CE mark approval
Xintong Medical-B (02160) announced that VitaFlow Liberty, independently developed by the group...
Microport Cardioflow Inks Services Deal With Subsidiary
Microport Cardioflow Medtech (HKG:2160) agreed to provide supporting services to its 51%-owned unit Shanghai MicroPort CardioAdvent for 2021, according to a Monday filing with the Hong Kong bourse. Th
Xintong Medical-B (02160.HK) signs 2024 Shanghai Jiuxin Service Procurement Framework Agreement
Gelonghui, April 15, 丨 Xintong Medical-B (02160.HK) announced that on April 15, 2024, the company (for itself and its subsidiaries, joint ventures and associated companies other than Shanghai Zuxin) entered into a 2024 Shanghai Jiuxin Service Procurement Framework Agreement for the period beginning on the 2024 Shanghai Jiuxin Service Procurement Framework Agreement and ending on December 31, 2025. According to this, Shanghai Zuxin will procure certain services from the company and its subsidiaries, joint ventures and associated companies other than Shanghai Jiuxin.
Xintong Medical-B (02160.HK) granted a total of 14.3238 million share options
Xintong Medical-B (02160.HK) issued an announcement. On April 8, 2024, the company decided to grant share options to eligible participants in accordance with the share plan adopted by the company on June 27, 2023 to subscribe for up to 14.3238 million shares of the company's common shares with a face value of 0.000005 US dollars per share. However, this can only be realized after acceptance by the grantor. The exercise price for which the share options were granted was HK$1.002 per share.
Xintong Medical-B (02160.HK): Revenue of 336 million yuan in 2023 increased by 33.9% year-on-year
Gelonghui, March 27 | Xintong Medical-B (02160.HK) announced that for the year ended December 31, 2023, revenue was approximately RMB 336 million, up 33.9% year on year; gross profit was approximately RMB 230 million, up 41.8% year on year; loss attributable to the company's equity shareholders was approximately RMB 472 million; loss attributable to the company's equity shareholders was approximately RMB 454 million; basic loss per share.
No Data